Hepatitis C is an infection caused by a virus that attacks the liver and leads to inflammation. Hepatitis C is one of several hepatitis viruses and is generally considered to be among the most serious of these viruses.
There is probably no better example of how innovations in biopharmaceutical research can impact disease treatment and reduce costs than by looking at the recent history of hepatitis C.
Thanks to advances in biotechnology, a once chronic and potentially fatal disease affecting millions of Americans, is now curable in over 90% of patients. A cure is defined as having no detectable hep C virus in the blood when measured three months after treatment is completed. As more patients gain access to these new treatments, we can expect to see a decline in the staggering costs of treating the disease.